Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | International Braz J Urol (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300484 |
Resumo: | ABSTRACT Prostate cancer is the most common invasive cancer in men. Radical prostatectomy (RP) is a definitive treatment option, but biochemical recurrence can reach 40%. Salvage lymphadenectomy is a relatively recent approach to oligometasis and has been rapidly diffused primarily due to improvement in imaging diagnosis and results showing possibly promising therapy. A systematic literature review was performed in March 2020, according to the PRISMA statement. We excluded studies with patients with suspicion or confirmation of visceral and / or bone metastases. A total of 27 articles were included in the study. All studies evaluated were single arm, and there were no randomized studies in the literature. A total of 1,714 patients received salvage lymphadenectomy after previous treatment for localized prostate cancer. RP was the most used initial therapeutic approach, and relapses were based on PET / CT diagnosis, with Coline-11C being the most widely used radiopharmaceutical. Biochemical response rates ranged from 0% to 80%. The 5 years - Free Survival Biochemical recurrence was analyzed in 16 studies with rates of 0% up to 56.1%. The articles do not present high levels of evidence to draw strong conclusions. However, even if significant rates of biochemical recurrence are not evident in all studies, therapy directed to lymph node metastases may present good oncological results and postpone the onset of systemic therapy. The long-term impact in overall survival and quality of life, as well as the best strategies for case selection remains to be determined. |
id |
SBU-1_1dafbfa5e0fbea6e4197dc64134cf73a |
---|---|
oai_identifier_str |
oai:scielo:S1677-55382021000300484 |
network_acronym_str |
SBU-1 |
network_name_str |
International Braz J Urol (Online) |
repository_id_str |
|
spelling |
Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic reviewProstate cance, familial [Supplementary Concept]Lymph NodesSystematic Reviews as TopicABSTRACT Prostate cancer is the most common invasive cancer in men. Radical prostatectomy (RP) is a definitive treatment option, but biochemical recurrence can reach 40%. Salvage lymphadenectomy is a relatively recent approach to oligometasis and has been rapidly diffused primarily due to improvement in imaging diagnosis and results showing possibly promising therapy. A systematic literature review was performed in March 2020, according to the PRISMA statement. We excluded studies with patients with suspicion or confirmation of visceral and / or bone metastases. A total of 27 articles were included in the study. All studies evaluated were single arm, and there were no randomized studies in the literature. A total of 1,714 patients received salvage lymphadenectomy after previous treatment for localized prostate cancer. RP was the most used initial therapeutic approach, and relapses were based on PET / CT diagnosis, with Coline-11C being the most widely used radiopharmaceutical. Biochemical response rates ranged from 0% to 80%. The 5 years - Free Survival Biochemical recurrence was analyzed in 16 studies with rates of 0% up to 56.1%. The articles do not present high levels of evidence to draw strong conclusions. However, even if significant rates of biochemical recurrence are not evident in all studies, therapy directed to lymph node metastases may present good oncological results and postpone the onset of systemic therapy. The long-term impact in overall survival and quality of life, as well as the best strategies for case selection remains to be determined.Sociedade Brasileira de Urologia2021-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300484International braz j urol v.47 n.3 2021reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2020.0051info:eu-repo/semantics/openAccessFantin,João Paulo PrettiFurst,Maria Claudia BicudoTobias-Machado,MarcosMuller,Roberto LodeiroMachado,Roberto DiasSantos,Alexandre CesarMagnabosco,Wesley JustinoAlcantara-Quispe,CinthiaFaria,Eliney Ferreiraeng2021-03-24T00:00:00Zoai:scielo:S1677-55382021000300484Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2021-03-24T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false |
dc.title.none.fl_str_mv |
Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review |
title |
Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review |
spellingShingle |
Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review Fantin,João Paulo Pretti Prostate cance, familial [Supplementary Concept] Lymph Nodes Systematic Reviews as Topic |
title_short |
Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review |
title_full |
Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review |
title_fullStr |
Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review |
title_full_unstemmed |
Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review |
title_sort |
Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review |
author |
Fantin,João Paulo Pretti |
author_facet |
Fantin,João Paulo Pretti Furst,Maria Claudia Bicudo Tobias-Machado,Marcos Muller,Roberto Lodeiro Machado,Roberto Dias Santos,Alexandre Cesar Magnabosco,Wesley Justino Alcantara-Quispe,Cinthia Faria,Eliney Ferreira |
author_role |
author |
author2 |
Furst,Maria Claudia Bicudo Tobias-Machado,Marcos Muller,Roberto Lodeiro Machado,Roberto Dias Santos,Alexandre Cesar Magnabosco,Wesley Justino Alcantara-Quispe,Cinthia Faria,Eliney Ferreira |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Fantin,João Paulo Pretti Furst,Maria Claudia Bicudo Tobias-Machado,Marcos Muller,Roberto Lodeiro Machado,Roberto Dias Santos,Alexandre Cesar Magnabosco,Wesley Justino Alcantara-Quispe,Cinthia Faria,Eliney Ferreira |
dc.subject.por.fl_str_mv |
Prostate cance, familial [Supplementary Concept] Lymph Nodes Systematic Reviews as Topic |
topic |
Prostate cance, familial [Supplementary Concept] Lymph Nodes Systematic Reviews as Topic |
description |
ABSTRACT Prostate cancer is the most common invasive cancer in men. Radical prostatectomy (RP) is a definitive treatment option, but biochemical recurrence can reach 40%. Salvage lymphadenectomy is a relatively recent approach to oligometasis and has been rapidly diffused primarily due to improvement in imaging diagnosis and results showing possibly promising therapy. A systematic literature review was performed in March 2020, according to the PRISMA statement. We excluded studies with patients with suspicion or confirmation of visceral and / or bone metastases. A total of 27 articles were included in the study. All studies evaluated were single arm, and there were no randomized studies in the literature. A total of 1,714 patients received salvage lymphadenectomy after previous treatment for localized prostate cancer. RP was the most used initial therapeutic approach, and relapses were based on PET / CT diagnosis, with Coline-11C being the most widely used radiopharmaceutical. Biochemical response rates ranged from 0% to 80%. The 5 years - Free Survival Biochemical recurrence was analyzed in 16 studies with rates of 0% up to 56.1%. The articles do not present high levels of evidence to draw strong conclusions. However, even if significant rates of biochemical recurrence are not evident in all studies, therapy directed to lymph node metastases may present good oncological results and postpone the onset of systemic therapy. The long-term impact in overall survival and quality of life, as well as the best strategies for case selection remains to be determined. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300484 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300484 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/s1677-5538.ibju.2020.0051 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Urologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Urologia |
dc.source.none.fl_str_mv |
International braz j urol v.47 n.3 2021 reponame:International Braz J Urol (Online) instname:Sociedade Brasileira de Urologia (SBU) instacron:SBU |
instname_str |
Sociedade Brasileira de Urologia (SBU) |
instacron_str |
SBU |
institution |
SBU |
reponame_str |
International Braz J Urol (Online) |
collection |
International Braz J Urol (Online) |
repository.name.fl_str_mv |
International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU) |
repository.mail.fl_str_mv |
||brazjurol@brazjurol.com.br |
_version_ |
1750318078052270080 |